Compare Edwards Lifesciences Corporation Common Stock (EW) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs Regeneron Pharmaceuticals Inc — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $84.08 (market cap $48.56B), while Regeneron Pharmaceuticals Inc trades at $746.55 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Edwards Lifesciences Corporation Common Stock pays none. Which is the better fit depends on your goals.
| EW | REGN | |
|---|---|---|
Market Cap | $48.56B | $76.14B |
Volume | 6,520,488 | 500,239 |
Sector | Health | Health |
52-Week High | $95.18 | $852.03 |
52-Week Low | $72.65 | $557.73 |
Enterprise Value | $45.01B | $70.85B |
Typical Hold Time | — | 107 Days |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
